The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 2, 2012, Pages 434-442

  Endo Munoz, Liliana ^a   Evdokiou, Andreas ^b   Saunders, Nicholas A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Metastasis; Microenvironment; Osteoclast; Osteosarcoma; Tumour associated macrophage

Indexed keywords

BONE REMODELING; CANCER GROWTH; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; HUMAN; METASTASIS; NONHUMAN; OSTEOCLAST; OSTEOSARCOMA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR PROMOTION;

ANIMALS; BONE NEOPLASMS; HUMANS; MACROPHAGES; OSTEOCLASTS; OSTEOSARCOMA;

EID: 84864800671     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.07.003     Document Type: Review

References (136)

1. Marina N., Gebhardt M., Teot L., Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004, 9:422-441.
2. Psaila B., Lyden D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 2009, 9:285-293.
3. Chirgwin J.M., Guise T.A. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit. Rev. Eukaryot. Gene Expr. 2000, 10:159-178.
4. Guise T.A. The vicious cycle of bone metastases. J. Musculoskelet. Neuronal Interact. 2002, 2:570-572.
5. Akiyama T., Dass C.R., Choong P.F. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol. Cancer Ther. 2008, 7:3461-3469.
6. Akiyama T., Dass C.R., Shinoda Y., Kawano H., Tanaka S., Choong P.F. Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts. J. Pharm. Pharmacol. 2010, 62:470-476.
7. Avnet S., Longhi A., Salerno M., Halleen J.M., Perut F., Granchi D., Ferrari S., Bertoni F., Giunti A., Baldini N. Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int. J. Oncol. 2008, 33:1231-1238.
8. Endo-Munoz L., Cumming A., Rickwood D., Wilson D., Cueva C., Ng C., Strutton G., Cassady A.I., Evdokiou A., Sommerville S., Dickinson I., Guminski A., Saunders N.A. Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Res. 2010, 70:7063-7072.
9. Endo-Munoz L., Cumming A., Sommerville S., Dickinson I., Saunders N.A. Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone. Br. J. Cancer 2010, 103:73-81.
10. Labrinidis A., Hay S., Liapis V., Ponomarev V., Findlay D.M., Evdokiou A. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions. Clin. Cancer Res. 2009, 15:3451-3461.
11. Labrinidis A., Hay S., Liapis V., Findlay D.M., Evdokiou A. Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model. Int. J. Cancer 2010, 127:345-354.
12. Mundy G.R. Mechanisms of bone metastasis. Cancer 1997, 80:1546-1556.
13. Guise T.A., Mohammad K.S., Clines G., Stebbins E.G., Wong D.H., Higgins L.S., Vessella R., Corey E., Padalecki S., Suva L., Chirgwin J.M. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res. 2006, 12:6213s-6216s.
14. Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 2008, 66:1-9.
15. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66:605-612.
16. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 2009, 86:1065-1073.
17. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
18. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2:584-593.
19. Bailey C., Negus R., Morris A., Ziprin P., Goldin R., Allavena P., Peck D., Darzi A. Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin. Exp. Metastasis 2007, 24:121-130.
20. Nonomura N., Takayama H., Nakayama M., Nakai Y., Kawashima A., Mukai M., Nagahara A., Aozasa K., Tsujimura A. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int. 2011, 107:1918-1922.
21. Osinsky S., Bubnovskaya L., Ganusevich I., Kovelskaya A., Gumenyuk L., Olijnichenko G., Merentsev S. Hypoxia, tumour-associated macrophages, microvessel density, VEGF and matrix metalloproteinases in human gastric cancer: interaction and impact on survival. Clin. Transl. Oncol. 2011, 13:133-138.
22. Pollard J.W. Macrophages define the invasive microenvironment in breast cancer. J. Leukoc. Biol. 2008, 84:623-630.
23. Lin E.Y., Pollard J.W. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007, 67:5064-5066.
24. Ojalvo L.S., King W., Cox D., Pollard J.W. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am. J. Pathol. 2009, 174:1048-1064.
25. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 2010, 22:231-237.
26. DeNardo D., Brennan D., Rexhepaj E., Ruffell B., Shiao S., Madden S., Gallagher W., Wadhwani N., Keil S., Junaid S., Rugo H., Hwang E., Jirstrom K., West B., Coussens L. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
27. Buddingh E.P., Kuijjer M.L., Duim R.A., Burger H., Agelopoulos K., Myklebost O., Serra M., Mertens F., Hogendoorn P.C., Lankester A.C., Cleton-Jansen A.M. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin. Cancer Res. 2011, 17:2110-2119.
28. Roodman G.D. Regulation of osteoclast differentiation. Ann. N. Y. Acad. Sci. 2006, 1068:100-109.
29. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
30. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
31. Stanley E.R., Berg K.L., Einstein D.B., Lee P.S., Pixley F.J., Wang Y., Yeung Y.G. Biology and action of colony-stimulating factor-1. Mol. Reprod. Dev. 1997, 46:4-10.
32. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
33. Chambers T.J. Regulation of the differentiation and function of osteoclasts. J. Pathol. 2000, 192:4-13.
34. Negishi-Koga T., Takayanagi H. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol. Rev. 2009, 231:241-256.
35. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3597-3602.
36. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., Morinaga T., Higashio K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 1998, 253:395-400.
37. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., Tan H.L., Elliott G., Kelley M.J., Sarosi I., Wang L., Xia X.Z., Elliott R., Chiu L., Black T., Scully S., Capparelli C., Morony S., Shimamoto G., Bass M.B., Boyle W.J. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3540-3545.
38. Teitelbaum S.L. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
39. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142:5050-5055.
40. Nakashima T., Takayanagi H. New regulation mechanisms of osteoclast differentiation. Ann. N. Y. Acad. Sci. 2011, 1240:E13-E18.
41. Xiong J., O'Brien C.A. Osteocyte RANKL: new insights into the control of bone remodeling. J. Bone Miner. Res. 2012, 27:499-505.
42. Lacey D.L., Tan H.L., Lu J., Kaufman S., Van G., Qiu W., Rattan A., Scully S., Fletcher F., Juan T., Kelley M., Burgess T.L., Boyle W.J., Polverino A.J. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 2000, 157:435-448.
43. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
44. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139:1329-1337.
45. Quinn J.M., McGee J.O., Athanasou N.A. Human tumour-associated macrophages differentiate into osteoclastic bone-resorbing cells. J. Pathol. 1998, 184:31-36.
46. Yang T.T., Sabokbar A., Gibbons C.L., Athanasou N.A. Human mesenchymal tumour-associated macrophages differentiate into osteoclastic bone-resorbing cells. J. Bone Joint Surg. Br. 2002, 84:452-456.
47. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292:490-495.
48. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front. Biosci. 2008, 13:453-461.
49. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3:23-35.
50. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
51. Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 2006, 177:7303-7311.
52. Mukhtar R.A., Nseyo O., Campbell M.J., Esserman L.J. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev. Mol. Diagn. 2011, 11:91-100.
53. Dougall W.C. RANKL signaling in bone physiology and cancer. Curr. Opin. Support. Palliat. Care 2007, 1:317-322.
54. Das S., Samant R.S., Shevde L.A. Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis. J. Biol. Chem. 2011, 286:9612-9622.
55. Yin J.J., Selander K., Chirgwin J.M., Dallas M., Grubbs B.G., Wieser R., Massague J., Mundy G.R., Guise T.A. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 1999, 103:197-206.
56. Kuo Y.C., Su C.H., Liu C.Y., Chen T.H., Chen C.P., Wang H.S. Transforming growth factor-beta induces CD44 cleavage that promotes migration of MDA-MB-435s cells through the up-regulation of membrane type 1-matrix metalloproteinase. Int. J. Cancer 2009, 124:2568-2576.
57. Goltzman D. Osteolysis and cancer. J. Clin. Invest. 2001, 107:1219-1220.
58. Stopeck A.T., Lipton A., Body J.J., Steger G.G., Tonkin K., de Boer R.H., Lichinitser M., Fujiwara Y., Yardley D.A., Viniegra M., Fan M., Jiang Q., Dansey R., Jun S., Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 2010, 28:5132-5139.
59. Coleman R. The use of bisphosphonates in cancer treatment. Ann. N. Y. Acad. Sci. 2011, 1218:3-14.
60. Roelofs A.J., Thompson K., Ebetino F.H., Rogers M.J., Coxon F.P. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr. Pharm. Des. 2010, 16:2950-2960.
61. Moriceau G., Ory B., Gobin B., Verrecchia F., Gouin F., Blanchard F., Redini F., Heymann D. Therapeutic approach of primary bone tumours by bisphosphonates. Curr. Pharm. Des. 2010, 16:2981-2987.
62. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71-78.
63. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007, 67:9518-9527.
64. Bottazzi B., Polentarutti N., Acero R., Balsari A., Boraschi D., Ghezzi P., Salmona M., Mantovani A. Regulation of the macrophage content of neoplasms by chemoattractants. Science 1983, 220:210-212.
65. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
66. Dirkx A.E., Oude Egbrink M.G., Wagstaff J., Griffioen A.W. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol. 2006, 80:1183-1196.
67. Goswami S., Sahai E., Wyckoff J.B., Cammer M., Cox D., Pixley F.J., Stanley E.R., Segall J.E., Condeelis J.S. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 2005, 65:5278-5283.
68. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
69. Pittet M.J. Behavior of immune players in the tumor microenvironment. Curr. Opin. Oncol. 2009, 21:53-59.
70. Zhu X., Mulcahy L.A., Mohammed R.A., Lee A.H., Franks H.A., Kilpatrick L., Yilmazer A., Paish E.C., Ellis I.O., Patel P.M., Jackson A.M. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 2008, 10:R95.
71. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N.R., Crystal R.G., Moore M.A., Hajjar K.A., Manova K., Benezra R., Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7:1194-1201.
72. Hiratsuka S., Nakamura K., Iwai S., Murakami M., Itoh T., Kijima H., Shipley J.M., Senior R.M., Shibuya M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002, 2:289-300.
73. Qian B., Deng Y., Im J.H., Muschel R.J., Zou Y., Li J., Lang R.A., Pollard J.W. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 2009, 4:e6562.
74. Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., Kaiser E.A., Snyder L.A., Pollard J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475(7355):222-225.
75. Zhang J., Lu Y., Pienta K.J. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J. Natl. Cancer Inst. 2010, 102:522-528.
76. Kim S.W., Kim J.S., Papadopoulos J., Choi H.J., He J., Maya M., Langley R.R., Fan D., Fidler I.J., Kim S.J. Consistent interactions between tumor cell IL-6 and macrophage TNF-alpha enhance the growth of human prostate cancer cells in the bone of nude mouse. Int. Immunopharmacol. 2011, 11:859-869.
77. Ottaviani G., Jaffe N. The epidemiology of osteosarcoma. Cancer Treat. Res. 2009, 152:3-13.
78. O'Day K., Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Rev. Anticancer Ther. 2009, 9:511-523.
79. Meyers P.A., Gorlick R. Osteosarcoma. Pediatr. Clin. North Am. 1997, 44:973-989.
80. Meyers P.A., Schwartz C.L., Krailo M., Kleinerman E.S., Betcher D., Bernstein M.L., Conrad E., Ferguson W., Gebhardt M., Goorin A.M., Harris M.B., Healey J., Huvos A., Link M., Montebello J., Nadel H., Nieder M., Sato J., Siegal G., Weiner M., Wells R., Wold L., Womer R., Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol. 2005, 23:2004-2011.
81. Hayden J.B., Hoang B.H. Osteosarcoma: basic science and clinical implications. Orthop. Clin. North Am. 2006, 37:1-7.
82. Khanna C., Khan J., Nguyen P., Prehn J., Caylor J., Yeung C., Trepel J., Meltzer P., Helman L. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 2001, 61:3750-3759.
83. Hughes D.P. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat. Res. 2009, 152:479-496.
84. Zhang P., Yang Y., Zweidler-McKay P.A., Hughes D.P. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin. Cancer Res. 2008, 14:2962-2969.
85. Fromigue O., Hamidouche Z., Vaudin P., Lecanda F., Patino A., Barbry P., Mari B., Marie P.J. CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis. J. Bone Miner. Res. 2011, 26:1533-1542.
86. McQueen P., Ghaffar S., Guo Y., Rubin E.M., Zi X., Hoang B.H. The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev. Anticancer Ther. 2011, 11:1223-1232.
87. Rubin E.M., Guo Y., Tu K., Xie J., Zi X., Hoang B.H. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol. Cancer Ther. 2010, 9:731-741.
88. Leow P.C., Tian Q., Ong Z.Y., Yang Z., Ee P.L. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Invest. New Drugs 2010, 28:766-782.
89. Kaya M., Wada T., Akatsuka T., Kawaguchi S., Nagoya S., Shindoh M., Higashino F., Mezawa F., Okada F., Ishii S. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin. Cancer Res. 2000, 6:572-577.
90. Yang S.Y., Yu H., Krygier J.E., Wooley P.H., Mott M.P. High VEGF with rapid growth and early metastasis in a mouse osteosarcoma model. Sarcoma 2007, 2007:95628.
91. Khanna C., Wan X., Bose S., Cassaday R., Olomu O., Mendoza A., Yeung C., Gorlick R., Hewitt S.M., Helman L.J. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med. 2004, 10:182-186.
92. Wan X., Kim S.Y., Guenther L.M., Mendoza A., Briggs J., Yeung C., Currier D., Zhang H., Mackall C., Li W.J., Tuan R.S., Deyrup A.T., Khanna C., Helman L. Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin. Oncogene 2009, 28:3401-3411.
93. Ren L., Hong S.H., Cassavaugh J., Osborne T., Chou A.J., Kim S.Y., Gorlick R., Hewitt S.M., Khanna C. The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene 2009, 28:792-802.
94. Worth L.L., Lafleur E.A., Jia S.F., Kleinerman E.S. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol. Rep. 2002, 9:823-827.
95. Gordon N., Koshkina N.V., Jia S.F., Khanna C., Mendoza A., Worth L.L., Kleinerman E.S. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin. Cancer Res. 2007, 13:4503-4510.
96. Kim S.Y., Lee C.H., Midura B.V., Yeung C., Mendoza A., Hong S.H., Ren L., Wong D., Korz W., Merzouk A., Salari H., Zhang H., Hwang S.T., Khanna C., Helman L.J. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin. Exp. Metastasis 2008, 25:201-211.
97. Pradelli E., Karimdjee-Soilihi B., Michiels J.F., Ricci J.E., Millet M.A., Vandenbos F., Sullivan T.J., Collins T.L., Johnson M.G., Medina J.C., Kleinerman E.S., Schmid-Alliana A., Schmid-Antomarchi H. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int. J. Cancer 2009, 125:2586-2594.
98. Meyers P.A. Malignant bone tumors in children: osteosarcoma. Hematol. Oncol. Clin. North Am. 1987, 1:655-665.
99. Kesselring F.O., Penn W. Radiological aspects of 'classic' primary osteosarcoma: value of some radiological investigations: A review. Diagn. Imaging 1982, 51:78-92.
100. Lamoureux F., Richard P., Wittrant Y., Battaglia S., Pilet P., Trichet V., Blanchard F., Gouin F., Pitard B., Heymann D., Redini F. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 2007, 67:7308-7318.
101. Dass C.R., Choong P.F. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol. Cancer Ther. 2007, 6:3263-3270.
102. Ory B., Heymann M.F., Kamijo A., Gouin F., Heymann D., Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005, 104:2522-2529.
103. Meyers P.A. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev. Anticancer Ther. 2009, 9:1035-1049.
104. Frampton J.E. Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr. Drugs 2010, 12:141-153.
105. Moon M.H., Jeong J.K., Seo J.S., Seol J.W., Lee Y.J., Xue M., Jackson C.J., Park S.Y. Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation. Exp. Mol. Med. 2011, 43:138-145.
106. Koto K., Murata H., Kimura S., Horie N., Matsui T., Nishigaki Y., Ryu K., Sakabe T., Itoi M., Ashihara E., Maekawa T., Fushiki S., Kubo T. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol. Rep. 2010, 24:233-239.
107. Molinuevo M.S., Bruzzone L., Cortizo A.M. Alendronate induces anti-migratory effects and inhibition of neutral phosphatases in UMR106 osteosarcoma cells. Eur. J. Pharmacol. 2007, 562:28-33.
108. Kubista B., Trieb K., Sevelda F., Toma C., Arrich F., Heffeter P., Elbling L., Sutterluty H., Scotlandi K., Kotz R., Micksche M., Berger W. Anticancer effects of zoledronic acid against human osteosarcoma cells. J. Orthop. Res. 2006, 24:1145-1152.
109. Evdokiou A., Labrinidis A., Bouralexis S., Hay S., Findlay D.M. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 2003, 33:216-228.
110. Hamilton E., Clay T.M., Blackwell K.L. New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Invest. 2011, 29:533-541.
111. Berenson J.R. Antitumor effects of bisphosphonates: from the laboratory to the clinic. Curr. Opin. Support. Palliat. Care 2011, 5:233-240.
112. Costa L., Harper P., Coleman R.E., Lipton A. Anticancer evidence for zoledronic acid across the cancer continuum. Crit. Rev. Oncol. Hematol. 2011, 77(Suppl. 1):S31-S37.
113. Daniele G., Giordano P., De Luca A., Piccirillo M.C., Di Maio M., Del Giudice A., De Feo G., Bryce J., Lamura L., Vecchione A., Normanno N., Perrone F. Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. Expert Rev. Anticancer Ther. 2011, 11:299-307.
114. Nicholas F.S., Saunders A., Thompson Erik W., Hill Michelle M., Endo-Munoz Liliana, Leggatt Graham, Minchin Rodney F., Guminski Alexander Role of intratumoral heterogeneity in cancer drug resistance: molecular and clinical perspectives, EMBO. Mol. Med. Jun 25 2012, 10.1002/emmm.201101131.
115. Barger A.M., Fan T.M., de Lorimier L.P., Sprandel I.T., O'Dell-Anderson K. Expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in neoplasms of dogs and cats. J. Vet. Intern. Med. 2007, 21:133-140.
116. Mori K., Le Goff B., Berreur M., Riet A., Moreau A., Blanchard F., Chevalier C., Guisle-Marsollier I., Leger J., Guicheux J., Masson M., Gouin F., Redini F., Heymann D. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J. Pathol. 2007, 211:555-562.
117. Molyneux S.D., Di Grappa M.A., Beristain A.G., McKee T.D., Wai D.H., Paderova J., Kashyap M., Hu P., Maiuri T., Narala S.R., Stambolic V., Squire J., Penninger J., Sanchez O., Triche T.J., Wood G.A., Kirschner L.S., Khokha R. Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J. Clin. Invest. 2010, 120:3310-3325.
118. Mintz M.B., Sowers R., Brown K.M., Hilmer S.C., Mazza B., Huvos A.G., Meyers P.A., Lafleur B., McDonough W.S., Henry M.M., Ramsey K.E., Antonescu C.R., Chen W., Healey J.H., Daluski A., Berens M.E., Macdonald T.J., Gorlick R., Stephan D.A. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005, 65:1748-1754.
119. Patino-Garcia A., Zalacain M., Folio C., Zandueta C., Sierrasesumaga L., San Julian M., Toledo G., De Las Rivas J., Lecanda F. Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin. Cancer Res. 2009, 15:5082-5091.
120. Zreiqat H., Howlett C.R., Gronthos S., Hume D., Geczy C.L. S100A8/S100A9 and their association with cartilage and bone. J. Mol. Histol. 2007, 38:381-391.
121. Wilson T.J., Nannuru K.C., Singh R.K. Cathepsin G recruits osteoclast precursors via proteolytic activation of protease-activated receptor-1. Cancer Res. 2009, 69:3188-3195.
122. Humphrey M.B., Ogasawara K., Yao W., Spusta S.C., Daws M.R., Lane N.E., Lanier L.L., Nakamura M.C. The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. J. Bone Miner. Res. 2004, 19:224-234.
123. Mocsai A., Humphrey M.B., Van Ziffle J.A., Hu Y., Burghardt A., Spusta S.C., Majumdar S., Lanier L.L., Lowell C.A., Nakamura M.C. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:6158-6163.
124. Hayman A.R. Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity 2008, 41:218-223.
125. Lee J., Kim K., Kim J.H., Jin H.M., Choi H.K., Lee S.H., Kook H., Kim K.K., Yokota Y., Lee S.Y., Choi Y., Kim N. Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood 2006, 107:2686-2693.
126. Chirgwin J.M., Guise T.A. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. J. Cell. Biochem. 2007, 102:1333-1342.
127. Meyers P.A., Schwartz C.L., Krailo M.D., Healey J.H., Bernstein M.L., Betcher D., Ferguson W.S., Gebhardt M.C., Goorin A.M., Harris M., Kleinerman E., Link M.P., Nadel H., Nieder M., Siegal G.P., Weiner M.A., Wells R.J., Womer R.B., Grier H.E. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J. Clin. Oncol. 2008, 26:633-638.
128. Nardin A., Lefebvre M.L., Labroquere K., Faure O., Abastado J.P. Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr. Cancer Drug Targets 2006, 6:123-133.
129. Kleinerman E.S., Meyers P.A., Raymond A.K., Gano J.B., Jia S.F., Jaffe N. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J. Immunother. Emphasis Tumor Immunol. 1995, 17:181-193.
130. Fidler I.J., Sone S., Fogler W.E., Barnes Z.L. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:1680-1684.
131. MacEwen E.G., Kurzman I.D., Rosenthal R.C., Smith B.W., Manley P.A., Roush J.K., Howard P.E. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J. Natl. Cancer Inst. 1989, 81:935-938.
132. Creaven P.J., Cowens J.W., Brenner D.E., Dadey B.M., Han T., Huben R., Karakousis C., Frost H., LeSher D., Hanagan J., et al. Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. J. Biol. Response Mod. 1990, 9:492-498.
133. Kurzman I.D., MacEwen E.G., Rosenthal R.C., Fox L.E., Keller E.T., Helfand S.C., Vail D.M., Dubielzig R.R., Madewell B.R., Rodriguez C.O., et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin. Cancer Res. 1995, 1:1595-1601.
134. Kleinerman E.S., Jia S.F., Griffin J., Seibel N.L., Benjamin R.S., Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J. Clin. Oncol. 1992, 10:1310-1316.
135. Smith B.W., Kurzman I.D., Schultz K.T., Czuprynski C.J., MacEwen E.G. Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells. Cancer Biother. 1993, 8:137-144.
136. Bielack S., Carrle D., Casali P.G. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2009, 20(Suppl. 4):137-139.